Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Smoking Cessation Treatment Escalation in Pancreatitis Patients
NCT07171112Phase 2Withdrawn
- Sponsor
- Mayo Clinic
- Start
- Nov 2025
- Primary completion
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of varenicline and bupropion in nicotine dependence (3 arms), sponsored by Mayo Clinic. Primary endpoint: Proportion of participants who quit smoking at 12 weeks. Planned start Nov 2025; status: withdrawn.
02
Drugs
vareniclinebupropion
03
Conditions
nicotine dependence
Beyond the preview
Go deeper on NCT07171112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07171112.